Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Avalo Therapeutics Inc AVTX

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the treatment of immune dysregulation by developing therapies that target the Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT)-signaling network. It is focused on advancing... see more

Recent & Breaking News (NDAQ:AVTX)

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire November 9, 2023

Avalo Completes Divestiture of AVTX-800 Series

GlobeNewswire October 31, 2023

BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics

TheNewsWire September 27, 2023

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

GlobeNewswire September 26, 2023

Avalo Enters into Agreement to Divest AVTX-800 Series

GlobeNewswire September 12, 2023

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire August 3, 2023

Avalo to Participate in SVB Securities Therapeutics Forum

GlobeNewswire July 6, 2023

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

GlobeNewswire June 26, 2023

Avalo to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board

GlobeNewswire May 22, 2023

Avalo to Present at ATS 2023 Respiratory Innovation Summit

GlobeNewswire May 15, 2023

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 10, 2023

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire May 4, 2023

Avalo Reports 2022 Financial Results and Provides Business Updates

GlobeNewswire March 29, 2023

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

GlobeNewswire March 7, 2023

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

GlobeNewswire February 2, 2023

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire February 2, 2023

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

GlobeNewswire January 17, 2023

Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates

GlobeNewswire November 7, 2022